Frequently Asked Questions

Why is the route of administration a primary variable for AAV PK profiles?

The selected route directly governs initial biodistribution, potential for off-target organ exposure, and interaction with the immune system. An intravenous injection results in systemic circulation and requires strategies to mitigate organ sequestration, whereas an intrathecal injection aims for localized central nervous system delivery, presenting its own distinct set of technical challenges.

What are the main translational challenges with intrathecal AAV delivery?

Achieving predictable and widespread transgene expression throughout the central nervous system via intrathecal delivery is complex. As demonstrated in translationally relevant models, the specific administration technique is a significant variable. Certain methods may fail to achieve meaningful spinal cord transduction, making the selection of a clinically relevant delivery protocol a key determinant of success (PMID: 32420410).

How does systemic IV administration impact the design of toxicology studies?

With IV administration, the AAV vector is distributed systemically, leading to high exposure in organs like the liver and spleen. IND-enabling toxicology studies must be designed to rigorously assess potential for organ-specific toxicity, monitor for systemic immune responses, and characterize transgene expression in a wide range of off-target tissues under GLP conditions.

Which models are most predictive for human CNS biodistribution?

Models with CNS anatomy and cerebrospinal fluid dynamics that closely mirror human physiology provide the most translationally relevant data. The anatomical and immunological similarities, including the volume and flow of cerebrospinal fluid, offer a more accurate prediction of vector distribution and potential immune responses compared to rodent models.

Tailoring Preclinical Strategy for AAV Pharmacokinetics

Selecting the correct route of administration for advanced therapeutics is a pivotal decision that dictates the entire preclinical development path for complex biologics. Applying proven intelligence in preclinical toxicology is necessary to accelerate these programs toward a successful IND submission. A standardized testing template does not exist for AAV vectors; the pharmacokinetic (PK) and biodistribution profile is inextricably linked to whether the vector is administered systemically or directly to a target compartment like the central nervous system (CNS).

Intravenous (IV) Administration Profiles

Systemic delivery via intravenous administration is a common approach for targeting the liver, muscle, and other tissues accessible from circulation. This route, however, presents distinct challenges that must be addressed in preclinical study design.

• Sufficient vector quantities are often required to achieve therapeutic efficacy.
• Significant vector sequestration in the liver can limit bioavailability for other target organs.
• The potential for inducing a robust systemic immune response to the AAV capsid is elevated.

Characterizing these effects in well-designed pharmacology studies is a prerequisite for designing definitive IND-enabling toxicology studies.

Intrathecal (IT) Administration for CNS Targets

For neurological indications, intrathecal administration is employed to bypass the blood-brain barrier and deliver the AAV vector directly into the cerebrospinal fluid (CSF). This localized approach aims to maximize transduction in the brain and spinal cord while minimizing systemic exposure.

The technical execution of IT delivery is a major variable. Preclinical feasibility evaluations have shown that not all administration techniques produce equivalent results. Data from biodistribution studies in relevant large animal models indicate that certain delivery methods may provide reproducible vector distribution, while others fail to achieve the desired level of spinal cord transduction. This underscores the need for rigorous procedural development and selection of the most clinically relevant administration paradigm.

A tailored preclinical strategy, informed by deep expertise in AAV biology and executed in the most relevant animal models, is the most effective way to minimize clinical risk and maintain a timeline of 18-24 months to IND.

Return to Preclinical | Translational Services Hub